rhabdomyolysis glp 1 Frontiers Glucagon-like peptide and its receptor

Some people naturally produce less GLP-1 or have a weaker GLP-1 response

"Application number 22-108 Cross Discipline Team Leader Review" (PDF)

Mathieu C, Dandona P, Gillard P et al (2018) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial

Making an informed choice requires understanding exactly what those differences mean for your treatment experience

Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations

But it's not a green light